Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

ABTC vs CHYM: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

CHYM Wins Head-to-Head Institutional Verdict (5–1 across 6 Pillars · 7–3 Matrix Metrics)

CHYM Overall Winner 6-Pillar Tally: ABTC 1 – 5 CHYM Matrix Metrics: ABTC 3 – 7 CHYM

As of Nov 16, 2026, Chime Financial, Inc. (CHYM) is the stronger overall head-to-head candidate over American Bitcoin Corp. (ABTC) in the Tradestie Institutional Equity Comparison Engine, winning 7–3 core matrix metrics and 5–1 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Balance Sheet & Cash Flow). ABTC carries a Unified Composite Score of 59.1/100 (HOLD) at $4.71 (4.9x Forward P/E, -38.7% operating margin), whereas CHYM carries 33.1/100 (SELL) at $34.29 (31.6x Forward P/E, 19.3% operating margin).

  • Composite vs. Pillar Nuance: While ABTC currently prints a higher short-term Unified Composite Score (59.1/100 HOLD vs. CHYM 33.1/100 SELL), CHYM captures the overall institutional head-to-head verdict (7–3 matrix metrics and 5–1 across the 6 pillars) due to superior fundamental profitability (19.3% vs. -38.7% operating margin) and revenue trajectory (+32.1% vs. -1.3% YoY).
  • Technical & Structure Timing Caution: ABTC is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 30.5); meanwhile CHYM trades in a Neutral technical trend (CONSOLIDATION options phase, RSI 73.1). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About ABTC vs CHYM
ABTC NASDAQ
American Bitcoin Corp. Class A Common Stock
Finance Services
$4.71
-7.1% 1D
Market Cap $369.2M
TTM Revenue $271M
Forward P/E 4.9x
Beta / 30D Vol 11.45β · 103% Vol
Unified Composite Score
59.1 / 100 HOLD
Tech 53.0 Fund 58.0 Flow 58.0 Mom 60.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -6.8%), weak momentum, RSI 31
RSI-14: 30.5 · SMA20: $6.46 · SMA50: $7.72
CHYM NASDAQ Head-to-Head Winner
Chime Financial, Inc. Class A Common Stock
Finance Services
$34.29
+2.21% 1D
Market Cap $12.9B
TTM Revenue $14.3B
Forward P/E 31.6x
Beta / 30D Vol 1.44β · 36% Vol
Unified Composite Score
33.1 / 100 SELL
Tech 15.0 Fund 33.0 Flow 57.0 Mom 30.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 73
RSI-14: 73.1 · SMA20: $30.52 · SMA50: $29.94

6-Pillar Scorecard Institutional Category Breakdown (ABTC 1 – 5 CHYM)

Columns: Metric · ABTC · CHYM
1. Valuation Multiples ABTC
Forward P/E 4.9x 31.6x
Trailing P/E 3.5x 29.4x
PEG Ratio N/M N/M
EV / Revenue 1.9x 0.7x
2. Growth & Scale CHYM
Revenue Growth (YoY) -1.3% +32.1%
Earnings Growth (YoY) N/A -33.8%
TTM Revenue (USD) $271M $14.3B
Market Cap $369.2M $12.9B
3. Profitability & Quality CHYM
Gross Margin 49.1% 89.4%
Operating Margin -38.7% 19.3%
Net Profit Margin -26.7% 3.0%
Return on Equity (ROE) -10.5% 5.4%
4. Balance Sheet & Cash Flow CHYM
Cash Generation (TTM) -$112M $2.27B
Cash Flow Margin -41.3% 15.8%
Net Cash / Leverage $148M Net Debt (0.19x D/E) $2.77B Net Cash
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning CHYM
Options Structure Phase BREAKDOWN CONSOLIDATION
Current IV / %ile 150.4% (9th %ile) 48.7% (12th %ile)
Put/Call OI Skew 0.05x (Call-Skewed) 0.22x (Call-Skewed)
OBV Trend / Tech Phase NEUTRAL · Markdown ACCUMULATION · Neutral
6. R&D & Supply-Chain Moat CHYM
OpEx & R&D Intensity N/A 70.1% of Rev ($10.1B)
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Scale & Operating Efficiency Moat
Supply-Chain Role Capital Markets Operator Software - Application Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: ABTC (3) vs CHYM (7)
Institutional Metric ABTC CHYM Criterion Row Edge
Market Capitalization
Scale
$369.2M $12.9B Larger Scale CHYM
Trailing P/E Ratio
Valuation
3.5x 29.4x Lower Multiple ABTC
Forward P/E Ratio
Valuation
4.9x 31.6x Lower Multiple ABTC
Revenue Growth (YoY)
Growth
-1.3% +32.1% Higher Growth CHYM
Operating Margin (TTM)
Profitability
-38.7% 19.3% Higher Margin CHYM
Net Profit Margin
Profitability
-26.7% 3.0% Higher Margin CHYM
Return on Equity (ROE)
Capital Efficiency
-10.5% 5.4% Higher ROE CHYM
52-Week Range Position
Momentum
40% ($1–$11) 94% ($16–$36) Stronger Trend CHYM
Beta / 30D Volatility
Risk Regime
11.45β · 103% Vol 1.44β · 36% Vol Lower Realized Risk CHYM
Unified Institutional Score
Composite Signal
59.1 / 100 (HOLD) 33.1 / 100 (SELL) Higher Composite ABTC
Trailing 12M Revenue (USD)
Operating Scale
$271M $14.3B FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
49.1% 89.4% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 1.9x EV/Rev N/M PEG · 0.7x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$112M ($148M Net Debt (0.19x D/E)) $2.27B ($2.77B Net Cash) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon CHYM +53.27 pp
ABTC: -37.7% · CHYM: +15.57%
3M Horizon CHYM +39.59 pp
ABTC: -32.13% · CHYM: +7.46%
6M Horizon ABTC +261.9 pp
ABTC: +357.28% · CHYM: +95.38%
1Y Horizon CHYM +79.32 pp
ABTC: -0.63% · CHYM: +78.69%

Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant USD Revenue & Operating Margin (%)
Period ABTC Revenue CHYM Revenue ABTC Op. Margin CHYM Op. Margin Margin Leader
FY2018 $10M N/A -23.5% N/A ABTC
FY2019 $10M N/A -115.6% N/A ABTC
FY2020 $10M N/A -137.4% N/A ABTC
FY2021 $20M N/A -187.8% N/A ABTC
FY2022 $10M N/A -412.0% N/A ABTC
FY2023 $60M $1.28B 9.6% -18.4% ABTC
FY2024 $70M $1.67B 676.7% -3.7% ABTC
FY2025 $190M $2.19B -123.1% -47.6% CHYM

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
ABTC BREAKDOWN
40d in phase · OBV NEUTRAL
Current IV 150.4%
IV Percentile 9th %ile
Put/Call OI Skew 0.05x (Call-Skewed)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact ABTC Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
CHYM CONSOLIDATION
48d in phase · OBV ACCUMULATION
Current IV 48.7%
IV Percentile 12th %ile
Put/Call OI Skew 0.22x (Call-Skewed)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow ACCUMULATION
Exact CHYM Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
LIVE OPTIONS CHAIN · T+5 TRADING DAY HORIZON Spot $34.29 · IV 48.7%

CHYM Simulated 5-Day Option Payoffs vs. Owning 100 Shares ($3,429)

Compare $3,429 in 100-share capital outlay against risk-defined 5-day vertical spreads, put-wall income, and 3-leg structures at 48.7% ATM IV.

5-DAY BULLISH SWING Liq B

Dec 18 $35 / $37.5 Bull Call Spread

Buy 1x $35C · Sell 1x $37.5C · 32d

Net Entry $91 Debit
T+5d @ +5% Move +$32 (+35%)
Max Risk / Buffer $91 Capped
5d Edge & Liquidity 0.8x R:R · Liq B
Simulate 5-Day Payoff →
PUT-WALL MONTHLY INCOME Liq B

Jan 15 '27 $30 / $27.5 Bull Put Spread

Sell 2x $30P · Buy 2x $27.5P · 60d

Net Entry $90 Credit
Max Credit / Yield +$90 (+22.0% RoM)
Max Risk / Buffer -13.8% Cushion ($410 Mgn)
5d Edge & Liquidity 79% PoP · Liq B
Simulate 5-Day Payoff →
5-DAY DOWNSIDE SPREAD Liq C

Dec 18 $35 / $32.5 Bear Put Spread

Buy 1x $35P · Sell 1x $32.5P · 32d

Net Entry $125 Debit
T+5d @ -5% Drop +$34 (+27%)
Max Risk / Buffer $125 Capped
5d Edge & Liquidity 0.8x R:R · Liq C
Simulate 5-Day Payoff →

Simulated T+5 trading day payoffs use live option midpoints, bid-ask spread adjustments, and implied volatility skew for educational scenario modeling only — not personalized investment advice. Options involve substantial risk.

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
ABTC Moat Profile Cyclical / Execution-Driven Positioning
Capital Markets Operator
Competes within the Capital Markets value chain with $369.2M market capitalization and -38.7% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
CHYM Moat Profile Scale & Operating Efficiency Moat
Software - Application Operator
Competes within the Software - Application value chain with $12.9B market capitalization and 19.3% operating margin.
OpEx & R&D Reinvestment 70.1% of Rev ($10.1B)
90D Engineering Disclosures 0 Published

Investor FAQ ABTC vs CHYM Key Questions & Quantitative Answers

As of Nov 16, 2026, Chime Financial, Inc. (CHYM) is the stronger overall head-to-head candidate over American Bitcoin Corp. (ABTC) in the Tradestie Institutional Equity Comparison Engine, winning 7–3 core matrix metrics and 5–1 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Balance Sheet & Cash Flow). ABTC carries a Unified Composite Score of 59.1/100 (HOLD) at $4.71 (4.9x Forward P/E, -38.7% operating margin), whereas CHYM carries 33.1/100 (SELL) at $34.29 (31.6x Forward P/E, 19.3% operating margin). Composite vs. Pillar Nuance: While ABTC currently prints a higher short-term Unified Composite Score (59.1/100 HOLD vs. CHYM 33.1/100 SELL), CHYM captures the overall institutional head-to-head verdict (7–3 matrix metrics and 5–1 across the 6 pillars) due to superior fundamental profitability (19.3% vs. -38.7% operating margin) and revenue trajectory (+32.1% vs. -1.3% YoY). Technical & Structure Timing Caution: ABTC is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 30.5); meanwhile CHYM trades in a Neutral technical trend (CONSOLIDATION options phase, RSI 73.1). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

CHYM leads the Growth & Scale pillar: ABTC posts -1.3% YoY revenue growth and N/A YoY earnings growth on $271M TTM revenue (49.1% gross margin, -38.7% operating margin), compared with CHYM at +32.1% YoY revenue growth and -33.8% YoY earnings growth on $14.3B TTM revenue (89.4% gross margin, 19.3% operating margin). Across the 8-period historical trajectory (FY2018 to FY2025), ABTC cumulative revenue shifted +1800.0% while CHYM shifted +71.1%. In operating R&D and SG&A reinvestment, ABTC deploys N/A (0 90-day corporate R&D disclosures) versus 70.1% of Rev ($10.1B) (0 disclosures) for CHYM.

ABTC screens cheaper on headline valuation multiples. ABTC trades at 4.9x Forward P/E, 3.5x Trailing P/E, N/M PEG, and 1.9x EV/Revenue (-41.3% FCF margin), whereas CHYM trades at 31.6x Forward P/E, 29.4x Trailing P/E, N/M PEG, and 0.7x EV/Revenue (15.8% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against ABTC (-10.5% ROE) versus CHYM (5.4% ROE) capital efficiency.

In options market volatility and institutional positioning, ABTC carries 150.4% implied volatility (9th %ile, Compressed (<25th %ile)), a 0.05x (Call-Skewed) Put/Call open-interest ratio, NEUTRAL on-balance volume, and sits in a BREAKDOWN options structure phase (11.45β · 103% Vol realized risk). By comparison, CHYM carries 48.7% implied volatility (12th %ile, Compressed (<25th %ile)), a 0.22x (Call-Skewed) Put/Call open-interest ratio, ACCUMULATION on-balance volume, and sits in a CONSOLIDATION options structure phase (1.44β · 36% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.